Paul Silva Biography and Net Worth

Paul M. Silva is Senior Vice President, Controller of the company, and he is no longer as Interim Chief Financial Officer, Effective April 10, 2019. Mr. Silva is our Senior Vice President and Corporate Controller, a position he has held since April 2011. Mr. Silva joined us in August 2007 as Senior Director, Accounting Operations and was our Vice President and Corporate Controller from September 2008 through April 2011. Prior to joining us, he was the Vice President, Internal Reporting at Iron Mountain Incorporated from July 2006 until August 2007 and a consultant to Iron Mountain’s financing department from April 2005 until July 2006. He was the Finance Director of the Bioscience Technologies Division of Thermo Electron Corporation from 2002 to April 2005. Mr. Silva holds a B.S. in accounting from Assumption College.

What is Paul M. Silva's net worth?: The estimated net worth of Paul M. Silva is at least $11.46 million as of February 11th, 2021. Mr. Silva owns 24,073 shares of Vertex Pharmaceuticals stock worth more than $11,458,267 as of October 31st. This net worth evaluation does not reflect any other investments that Mr. Silva may own. Learn More about Paul M. Silva's net worth.
How do I contact Paul M. Silva?: The corporate mailing address for Mr. Silva and other Vertex Pharmaceuticals executives is 50 NORTHERN AVENUE, BOSTON MA, 02210. Vertex Pharmaceuticals can also be reached via phone at (617) 341-6100 and via email at [email protected]. Learn More on Paul M. Silva's contact information.
Has Paul M. Silva been buying or selling shares of Vertex Pharmaceuticals?: Paul M. Silva has not been actively trading shares of Vertex Pharmaceuticals during the last quarter. Most recently, Paul M. Silva sold 1,498 shares of the business's stock in a transaction on Thursday, February 11th. The shares were sold at an average price of $210.57, for a transaction totalling $315,433.86. Following the completion of the sale, the chief accounting officer now directly owns 24,073 shares of the company's stock, valued at $5,069,051.61. Learn More on Paul M. Silva's trading history.
Who are Vertex Pharmaceuticals' active insiders?: Vertex Pharmaceuticals' insider roster includes David Altshuler (EVP), Kristen Ambrose (CAO), Stuart Arbuckle (COO), E. Morrey Atkinson, III (EVP), Sangeeta Bhatia (Director), Jonathan Biller (EVP), Joshua Boger (Director), Carmen Bozic (CMO), Reshma FASN (M.D.), Reshma Kewalramani (CEO), Yuchun Lee (Director), Jeffrey Leiden (Chairman), Joy Liu (SVP), Margaret McGlynn (Director), Michael Parini (EVP), Amit Sachdev (EVP), Bruce Sachs (Director), Bastiano Sanna (EVP), Paul Silva (CAO), Ian Smith (COO), Ourania Tatsis (EVP), and Charles Wagner, Jr. (CFO). Learn More on Vertex Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Vertex Pharmaceuticals?: During the last year, insiders at the pharmaceutical company sold shares 24 times. They sold a total of 96,063 shares worth more than $43,158,852.08. The most recent insider tranaction occured on August, 30th when Chairman Jeffrey M Leiden sold 3,784 shares worth more than $1,888,216.00. Insiders at Vertex Pharmaceuticals own 0.2% of the company. Learn More about insider trades at Vertex Pharmaceuticals.
Information on this page was last updated on 8/30/2024.

Paul M. Silva Insider Trading History at Vertex Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/11/2021	Sell	1,498	$210.57	$315,433.86	24,073
7/13/2020	Sell	860	$292.03	$251,145.80	15,792
5/6/2020	Sell	1,076	$272.74	$293,468.24	15,397
5/4/2020	Sell	809	$260.87	$211,043.83	15,741
4/13/2020	Sell	859	$248.72	$213,650.48	15,791
4/6/2020	Sell	4,891	$255.57	$1,249,992.87	19,823
1/13/2020	Sell	860	$229.38	$197,266.80	18,619
1/8/2020	Sell	13,750	$231.89	$3,188,487.50	31,509
1/2/2020	Sell	25,630	$218.92	$5,610,919.60	34,517
5/15/2019	Sell	161	$165.41	$26,631.01	17,759
2/19/2019	Sell	2,812	$186.97	$525,759.64	18,903
2/11/2019	Sell	4,215	$180.16	$759,374.40	23,386
2/6/2019	Sell	1,289	$193.00	$248,777.00	13,938
2/4/2019	Sell	4,247	$187.02	$794,273.94	16,896
1/17/2019	Sell	3,007	$190.62	$573,194.34	17,376
12/3/2018	Sell	809	$186.52	$150,894.68	16,896
11/15/2018	Sell	12	$163.75	$1,965.00	16,087
8/3/2018	Sell	2,098	$174.44	$365,975.12	17,376
7/16/2018	Sell	860	$179.85	$154,671.00	16,947
7/12/2018	Sell	860	$175.02	$150,517.20	16,947
6/29/2018	Sell	2,957	$166.52	$492,399.64	16,946
5/15/2018	Sell	201	$155.78	$31,311.78	16,087
4/18/2018	Sell	859	$166.05	$142,636.95	16,946
4/2/2018	Sell	3,438	$161.21	$554,239.98	16,225
2/20/2018	Sell	3,437	$158.49	$544,730.13	19,525
2/12/2018	Sell	4,213	$153.41	$646,316.33
2/5/2018	Sell	2,098	$163.08	$342,141.84	17,923
2/2/2018	Sell	9,883	$173.50	$1,714,700.50	25,228
1/23/2018	Sell	5,435	$164.03	$891,503.05	19,061
12/27/2017	Sell	1,289	$152.31	$196,327.59	17,923
8/7/2017	Sell	1,289	$152.88	$197,062.32	17,923
8/2/2017	Sell	1,289	$151.80	$195,670.20	17,923
7/31/2017	Sell	860	$152.99	$131,571.40	17,494
7/21/2017	Sell	43,443	$161.07	$6,997,364.01	26,516
6/21/2017	Sell	2,577	$133.36	$343,668.72	22,648
3/29/2017	Sell	1,688	$106.30	$179,434.40	21,759
11/10/2016	Sell	5,062	$90.98	$460,540.76	17,125
5/9/2016	Sell	3,000	$87.63	$262,890.00	15,950
2/3/2016	Sell	5,062	$90.82	$459,730.84	16,750
7/13/2015	Sell	1,125	$123.79	$139,263.75
5/5/2015	Sell	4,101	$123.68	$507,211.68
4/27/2015	Sell	1,125	$129.74	$145,957.50
4/13/2015	Sell	1,125	$128.60	$144,675.00
3/23/2015	Sell	2,250	$125.65	$282,712.50
2/5/2015	Sell	1,688	$109.75	$185,258.00
2/3/2015	Sell	2,063	$108.89	$224,640.07
1/26/2015	Sell	1,125	$125.62	$141,322.50
12/12/2014	Sell	2,813	$120.08	$337,785.04
11/28/2014	Sell	8,164	$119.85	$978,455.40
10/27/2014	Sell	1,125	$110.03	$123,783.75
10/13/2014	Sell	1,125	$107.89	$121,376.25
9/19/2014	Sell	25,408	$99.85	$2,536,988.80
7/31/2014	Sell	2,027	$88.97	$180,342.19
7/25/2013	Sell	1,125	$86.49	$97,301.25
7/16/2013	Sell	2,063	$86.25	$177,933.75

Paul M. Silva Buying and Selling Activity at Vertex Pharmaceuticals

Vertex Pharmaceuticals Company Overview

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $475.98

$468.98

$477.70

50 Day Range

MA: $474.81

$448.60

$498.73

2 Week Range

Now: $475.98

$341.90

$510.64

Volume

1,375,027 shs

Average Volume

1,166,011 shs

Market Capitalization

$122.85 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.4

Election warning coming true…

From Porter & Company | Ad

If you missed it, my emergency election broadcast is now available - watch it before it's too late.

Click here to watch it now.